A Randomized, Double-Blind Placebo-Controlled Exploration of a Topical Menadione-Containing Lotion to the Face for Prevention and Palliation of Epidermal Growth Factor Receptor Inhibitor-Induced Cutaneous Discomfort and Psychological Distress
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 17 Oct 2019
Price : $35 *
At a glance
- Drugs Menadione (Primary)
- Indications Exanthema
- Focus Therapeutic Use
- 04 Apr 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 04 Apr 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
- 05 Feb 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.